2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease courseSociodemographic disparities in prostate cancer imaging
Sundaresan V, Lokeshwar S, Sutherland R, Sohoni N, Golos A, Ajjawi I, Leapman M. Sociodemographic disparities in prostate cancer imaging. Abdominal Radiology 2024, 1-9. PMID: 39325212, DOI: 10.1007/s00261-024-04603-2.Peer-Reviewed Original ResearchProstate cancer imagingProstate cancerProstate cancer diagnosisMonitoring of prostate cancerProstate multiparametric MRISociodemographic disparitiesProstate cancer treatmentEquitable cancer careBiochemical recurrenceFactors associated with disparitiesMultiparametric MRIActive surveillanceTreatment planningBlack patientsCancer outcomesTreatment workflowDiagnostic imagingCancer careDiagnosisRural settingsProstateImaging utilizationTreatmentPatientsCancer imagingAssociation Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024 PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.Peer-Reviewed Original ResearchDecipher genomic classifierRisk of metastasisBiochemical recurrenceRadical prostatectomyGenomic classifierDecipher testProstate cancerProstate Risk Assessment Postsurgical ScoreRisk of biochemical recurrencePatient's prostate cancerRisk of cancer recurrencePathological risk factorsProstate cancer outcomesCox proportional hazards regressionRetrospective cohort studyElectronic health record dataReal-world settingsProportional hazards regressionHealth record dataReal-world practice settingsProstate biopsyRP specimensOncological outcomesPrognostic significanceMedian age
2018
Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy.
Leapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, Cooperberg M, Carroll P. Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 118-118. DOI: 10.1200/jco.2018.36.6_suppl.118.Peer-Reviewed Original ResearchPCa-specific mortalityRadical prostatectomyBiochemical recurrenceCCP scoreIHC panelCell cycle progression scoreExpression statusERG expressionCox proportional hazards regressionRisk of BCRPositive ERG expressionProportional hazards regressionProstate cancer riskPrediction of outcomeHigh Ki67Median ageIndependent predictorsPathologic characteristicsHazards regressionPrognostic utilityIHC statusInstitutional databaseLocalized PCaC-indexImmunohistochemistry panel
2016
Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy
Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal Of Urology 2016, 196: 1408-1414. PMID: 27352635, PMCID: PMC5542578, DOI: 10.1016/j.juro.2016.06.086.Peer-Reviewed Original ResearchConceptsAfrican American raceLow-risk prostate cancerAfrican American menRisk prostate cancerCaucasian manProstate cancerPathological upgradingBiochemical recurrenceFive-year recurrence-free survival ratesClinical low‐risk prostate cancerClinical low-risk diseaseRecurrence-free survival ratesCox proportional hazards analysisBiochemical recurrence outcomesEqual-access health systemLow-risk diseaseCohort of patientsLow-risk tumorsPositive surgical marginsProportional hazards analysisSearch databasesSEARCH cohortRecurrence outcomesRisk diseaseRisk tumorsMP80-01 PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IS NOT ASSOCIATED WITH BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY FOR PROSTATE CANCER
Leapman M, Nguyen H, Cowan J, Porten S, Meng M, Cooperberg M, Carroll P. MP80-01 PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IS NOT ASSOCIATED WITH BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY FOR PROSTATE CANCER. Journal Of Urology 2016, 195: e1043. DOI: 10.1016/j.juro.2016.02.2033.Peer-Reviewed Original ResearchPhosphodiesterase type 5 inhibitor useType 5 inhibitor useInhibitor useBiochemical recurrenceProstate cancerRelationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer.
Leapman M, Cowan J, Nguyen H, Porten S, Cooperberg M, Carroll P. Relationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer. Journal Of Clinical Oncology 2016, 34: 119-119. DOI: 10.1200/jco.2016.34.2_suppl.119.Peer-Reviewed Original ResearchPhosphodiesterase type 5 inhibitorsBiochemical recurrenceType 5 inhibitorsProstate cancerUse of PDE5iMedian age 61 yearsMedian age 69 yearsProstate Strategic Urologic Research EndeavorRisk of BCRCox proportional hazards modelAndrogen deprivation therapyAge 61 yearsAge 69 yearsKaplan-Meier methodSexual function scoresCohort of menProportional hazards modelDeprivation therapyPrescription complianceDefinitive therapyTime-dependent useDefinitive treatmentDisease recurrenceClinical evidenceBaseline usePathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy.
Leapman M, Freedland S, Aaronson W, Kane C, Terris M, Amling C, Carroll P, Cooperberg M. Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy. Journal Of Clinical Oncology 2016, 34: 76-76. DOI: 10.1200/jco.2016.34.2_suppl.76.Peer-Reviewed Original ResearchBiochemical recurrenceAA raceCaucasian manProstate cancerAA menCaucasian raceEqual Access Regional Cancer Hospital (SEARCH) databaseClinical low-risk diseaseLow-risk prostate cancerRecurrence-free survival ratesCox proportional hazards analysisAdverse pathological findingsEqual-access health systemHigher median PSAImmediate radical prostatectomyLow-risk diseaseLow-risk tumorsPositive surgical marginsProportional hazards analysisLow-risk menAfrican American menUse of ASGleason upgradePathologic upgradingPathological upgrade